Ablative Solutions Overview
- Founded
-
2011
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$91.4M
- Investors
-
8
Ablative Solutions General Information
Description
Operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic hypertension. The company has developed the Peregrine System Infusion Catheter to perform chemical renal denervation, using alcohol as the neurolytic agent, which may have substantial advantages over energy-based systems, enabling clinicians to help reduce blood pressure for patients with hypertension that is not well controlled.
Contact Information
Website
www.ablativesolutions.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Surgical Devices
Other Industries
Other Devices and Supplies
Primary Office
- 301 Edgewater Place
- Suite 100
- Wakefield, MA 01880
- United States
+1 (650) 000-0000
Ablative Solutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series D) | 13-Jun-2022 | $91.4M | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 5. Secondary Transaction - Private | 000.00 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series C) | 01-Mar-2017 | 000.00 | 000.00 | 0000 | Completed | Clinical Trials - Phase 3 |
| 3. Early Stage VC (Series B) | 30-Oct-2015 | 000.00 | 000.00 | 000.00 | Completed | Startup |
| 2. Early Stage VC (Series A) | 19-Jun-2012 | $5.37M | $12.3M | 000.00 | Completed | Startup |
| 1. Early Stage VC | 10-Feb-2012 | $6.92M | $6.92M | Completed | Startup |
Ablative Solutions Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D2 | 00,000,000 | 00.000000 | 00 | 00.0 | 00.0 | 00 | 00.0 | 00.00 |
| Series D1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.00 |
| Series C | 0,000,000 | 00.000000 | 00 | 00.0 | 00.00 | 00 | 00.0 | 00.000 |
| Series B | 2,805,392 | $0.001000 | 8% | $5.57 | $8.36 | 1x | $5.57 | 4.03% |
| Series A | 1,287,757 | $0.001000 | 8% | $3.85 | $5.78 | 1x | $2.3 | 3.1% |
Ablative Solutions Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a clinical-stage medical device company intended to address the significant unmet clinical need for systemic
Surgical Devices
Wakefield, MA
42
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000
onsectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
00000000 0000000
New York, NY
000
As of 0000
000.00
000000 - 000
000.00
000000
ation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderi
00000000 0000000
Trumbull, CT
Add Comparison
Ablative Solutions Competitors (13)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Angiodynamics | Corporation | New York, NY | 000 | 000.00 | 000000 - 000 | 000.00 |
| 00000000000000 | Corporate Backed or Acquired | Trumbull, CT | ||||
| 0000000000 | Private Equity-Backed | Redwood City, CA | 000 | 00000 | 000000000 | 00000 |
| 000000000 00000000 | Venture Capital-Backed | Minneapolis, MN | 000 | 00000 | 00000000000 | 00000 |
| 00000000000 | Venture Capital-Backed | Plymouth, MN | 00 | 00000 | 0000000000 0 |
Ablative Solutions Patents
Ablative Solutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160045257-A1 | Method for selection and treatment of hypertensive patients with renal denervation | Abandoned | 14-Aug-2014 | 000000000 | 0 |
| US-10517666-B2 | Apparatus for effective ablation and nerve sensing associated with denervation | Active | 25-Oct-2013 | 00000000000 | 000 |
| US-20190008580-A1 | Apparatus for effective ablation and nerve sensing associated with denervation | Granted | 25-Oct-2013 | 00000000000 | 0 |
| US-10022059-B2 | Apparatus for effective ablation and nerve sensing associated with denervation | Active | 25-Oct-2013 | 00000000000 | 00 |
| US-20190015002-A1 | Apparatus for effective ablation and nerve sensing associated with denervation | Granted | 25-Oct-2013 | A61B5/04001 | 0 |
Ablative Solutions Executive Team (11)
Ablative Solutions Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Tochterman | Ablative Solutions | Board Member | 000 0000 |
| Benjamin Tsai | Self | Board Member | 000 0000 |
| Dale Grogan | Michigan Accelerator Fund 1 | Board Member | 000 0000 |
| David Fischell Ph.D | Self | Co-Founder & Board Member | 000 0000 |
| Geoff Pardo | Gilde Healthcare Partners | Board Member | 000 0000 |
Ablative Solutions Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ablative Solutions Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Gilde Healthcare Partners | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Invus Opportunities | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Dempsey Ventures | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| GlobalLink1 Capital | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| BioStar Capital | Venture Capital | Minority | 000 0000 | 000000 0 |